Semma Therapeutics

Semma Therapeutics was founded to develop transformative therapies for patients who currently depend on insulin injections. Recent work in the laboratory of Professor Douglas Melton led to the discovery of a method to generate billions of functional, insulin-producing beta cells in the laboratory. These cells develop in islet-like clusters grown from stem cells. Initial preclinical work in animal models of diabetes has shown that transplantation of these cells are sufficient to control blood glucose levels. This breakthrough technology has been exclusively licensed to Semma Therapeutics for the development of a cell-based therapy for diabetes. Ongoing research at Semma Therapeutics is focused on combining these proprietary cells with a state-of-the-art cell delivery and immune protection strategy that can protect these cells from the patient’s immune system and allow the beta cells to function as they do in non-diabetic individuals. Implantation of the beta cell-filled device has the potential to provide a true replacement for the missing beta cells in a diabetic patient and would not require patient immunosuppression. Semma Therapeutics is working to bring this new therapeutic option to the clinic and improve the lives of patients with diabetes.
Company Growth (employees)
Type
Private
HQ
Cambridge, US
Founded
2015
Size (employees)
29 (est)
Semma Therapeutics was founded in 2015 and is headquartered in Cambridge, US

Semma Therapeutics Office Locations

Semma Therapeutics has offices in Cambridge and Providence
Cambridge, US (HQ)
2b 450 Kendall St
Providence, US
107 117 Chapman St

Semma Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2015

Total Funding

$163 m

Latest funding size

$114 m

Time since last funding

14 days

Investors

Semma Therapeutics's latest funding round in November 2017 was reported to be $114 m. In total, Semma Therapeutics has raised $163 m

Semma Therapeutics's Web-traffic and Trends

Semma Therapeutics Company Life and Culture

You may also be interested in